1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €15.47 (+360.42%). The median is €14.61 (+334.82%).
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -10.09M | 4.78% |
| EBITDA | -10.84M | 12.61% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €73.17M |
Number of shares | 21.83M |
52-week high/low | €10.21 - €2.60 |
| Dividends | No |
Beta | 0.21 |
P/E ratio | -1.93 |
PEG ratio | -0.01 |
P/B ratio | 1.61 |
P/S ratio | 0.00 |
Company profile
Kalaris Therapeutics Inc. ist ein pharmazeutisches Unternehmen. Das Unternehmen ist auf die Entwicklung neuartiger Zelltherapien spezialisiert, deren Schwerpunkt auf der Wiederherstellung der natürlichen Immunität gegen lebensbedrohliche virusbedingte Krankheiten bei Patienten mit stark geschwächtem Immunsystem liegt.
| Name | Kalaris Therapeutics Inc |
| CEO | Andrew Oxtoby |
| Website | |
| IPO | 07/30/2020 |
| Employees | 20 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | KLRS |
Discover assets
Shareholders of Kalaris Therapeutics Inc also invest in the following assets
